Unusual xanthomas in a young patient with heterozygous familial hypercholesterolemia and type III hyperlipoproteinemia

American Journal of Medical Genetics

Volumn 65, Issue 2, 1996, Pages 149-154

  Feussner, Giso ^a   Dobmeyer, Jürgen ^a   Nissen, Henrik ^b   Hansen, Torben Stiig ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

apolipoprotein E; familial dysbetalipoproteinemia; familial hypercholesterolemia; type III hyperlipoproteinemia; xanthomas

Indexed keywords

APOLIPOPROTEIN E;

ADULT; ARTICLE; CASE REPORT; DENATURING GRADIENT GEL ELECTROPHORESIS; DNA SEQUENCE; FAMILIAL HYPERCHOLESTEROLEMIA; GENE LOCUS; HOMOZYGOSITY; HUMAN; HYPERLIPOPROTEINEMIA; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MALE; PHENOTYPE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; XANTHOMA;

ADOLESCENT; ADULT; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEINS E; CHILD; FEMALE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; HYPERLIPOPROTEINEMIA TYPE III; LIPIDS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; MUTATION; PEDIGREE; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROMOTER REGIONS (GENETICS); RECEPTORS, LDL; XANTHOMATOSIS;

EID: 0029967025     PISSN: 01487299     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8628(19961016)65:2<149::AID-AJMG14>3.0.CO;2-Q     Document Type: Article

References (29)

1. Brewer HB Jr, Zech LA, Gregg RE, Schwartz D, Schaefer EJ (1983): Type III hyperlipoproteinemia: Diagnosis, molecular defects, pathology, and treatment. Ann Intern Med 98:623-640.
2. Davignon J, Gregg RE, Sing CF (1988): Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 8:1-21.
3. Feussner G, Wingen AM, Ziegler R (1990): Type III hyperlipoproteinemia in a child with hemolytic uremic syndrome. Metabolism 39:1196-1199.
4. Feussner G, Eichinger M, Ziegler R (1992): The influence of simvastatin alone and in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipoproteinemia. Clin Investig 70:1027-1035.
5. Feussner G, Wagner A, Kohl B, Ziegler R (1993a): Clinical features of type III hyperlipoproteinemia: Analysis of 64 patients. Clin Investig 71:362-366.
6. Feussner G, Wagner A, Ziegler R (1993b): Relation of cardiovascular risk factors to atherosclerosis in type III hyperlipoproteinemia. Hum Genet 92:122-126.
7. Glueck CJ, Fallat RW, Mollis MJ, Steiner PM (1976): Pediatric familial type III hyperlipoproteinemia. Metabolism 25:1269-1274.
8. Godolphin WJ, Conradi G, Campbell DJ (1972): Type-III hyperlipoproteinemia in a child. Lancet 1:209-210.
9. Goldstein JL, Brown MS (1989): Familial hypercholesterolemia. In Scriver CR, Beaudet AL, Sly WS, Valle D (eds): "The Metabolic Basis of Inherited Disease," 6th ed. New York: McGraw-Hill Book Co., pp 1215-1250.
10. Grundy SC (1988): HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 319:24-33.
11. Havel RJ, Kotite L, Kane JP, Tun P, Bersot T (1983): Atypical familial dysbetalipoproteinemia associated with apolipoprotein phenotype E3/3. J Clin Invest 72:379-387.
12. Hazzard WR, Miller N, Albers JJ, Warnick GR, Baron P, Lewis B (1981): Association of isoapolipoprotein-E3 deficiency with heterozygous familial hypercholesterolaemia: Implications for lipoprotein physiology. Lancet 1:298-301.
13. Hobbs HH, Brown MS, Goldstein JL (1992): Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1:445-466.
14. Leren TP, Solberg K, Rodningen OK, Tonstad S, Ose L (1994): Two founder mutations in the LDL receptor gene in Norwegian familial hypercholesterolemia subjects. Atherosclerosis 111:175-182.
15. Lindner MA, Illingworth DR (1988): Expression of type III hyperlipoproteinemia in an adolescent patient with hypothyroidism. J Pediatr 113:86-89.
16. Mabuchi H, Itoh H, Takeda M, Kajinami K, Wakasugi T, Koizumi J, Takeda R, Asagami C (1989): A young type III hyperlipoproteinemic patient associated with apolipoprotein E deficiency. Metabolism 38:115-119.
17. Mahley RW, Rall SC, Jr (1989): Type III hyperlipoproteinemia (dysbetalipoproteinemia): The role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In Scriver CR, Beaudet AL, Sly WS, Valle D (eds): "The Metabolic Basis of Inherited Disease," 6th ed. New York: McGraw-Hill Book Co., pp 1195-1213.
18. Mishkel MA, Nazir DJ, Crowther S (1975): A longitudinal assessment of lipid ratios in the diagnosis of type III hyperlipoproteinemia. Clin Chim Acta 58:121-136.
19. Nestel PJ, Reardon MF, Fidge NH (1984): Homozygous familial hypercholesterolemia occurring with apolipoprotein E3 deficiency. Report of two cases. Arteriosclerosis 4:124-129.
20. Nissen H, Guldberg P, Hansen AB, Petersen NE, Horder M (1996): Clinically applicable mutation screening in familial hypercholesterolemia. Hum Mutat, in press.
21. Nissen H, Hansen PS, Faergeman O, Horder M (1995): Mutant screening of the codon 3500 region of the apolipoprotein B gene by denaturing gradient-gel electrophoresis. Clin Chem 41:419-423.
22. Rall SC Jr, Newhouse YM, Clarke HRG, Weisgraber KH, McCarthy BJ, Mahley RW, Bersot TP (1989): Type III hyperlipoproteinemia associated with apolipoprotein phenotype E3/3: Structure and genetics of a rare apolipoprotein E3 variant. J Clin Invest 83: 1095-1101.
23. Sakuma N, Iwata S, Ikeuchi R, Ichikawa T, Hibino T, Kamiya Y, Ohte N, Kawaguchi M, Junimatsu M, Kawahara H, Fujinami T (1995): Coexisting type III hyperlipoproteinemia and familial hypercholesterolemia: A case report. Metabolism 44:460-465.
24. Schneider WJ, Kovanen PT, Brown MS, Goldstein JL, Utermann G, Weber W, Havel RJ, Kotite L, Kane JP, Innerarity TL, Mahley RW (1981): Familial dysbetalipoproteinemia: Abnormal binding of mutant apolipoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenals of rats, rabbits and cows. J Clin Invest 68:1075-1085.
25. Soutar AK (1992): A polymorphism in exon 2 of the human LDL-receptor gene (LDLR). Nucleic Acids Res 19:4314.
26. Stuyt PMJ, Mol MJTM, Stalenhoef AFH, Demacker PNM, van't Laar A (1990): Simvastatin in the effective reduction of plasma lipoprotcin levels in familial dysbetalipoproteinemia (type III hyperlipoproteinemia). Am J Med 88:42N-45N.
27. Stuyt PMN, Mol MJTM, Stalenhoef AFH (1991): Long-term effects of simvastatin in familial dysbetalipoproteinaemia. J Intern Med 230:151-155.
28. Sun X-M, Patel DD, Bhatnagar D, Knight BL, Soutar AK (1995): Characterization of a splice-site mutation in the gene for the LDL receptor associated with an unpredictably severe clinical phenotype in English patients with heterozygous FH. Arterioscler Thromb Vasc Biol 15:219-227.
29. Warnick GR, Mayfield C, Albers JJ, Hazzard WR (1979): Gel isoelectric focusing method for specific diagnosis of familial hyperlipoproteinemia type 3. Clin Chem 25:279-284.